Vaccine Strategy During the SARS-CoV-2 Pandemic: What School Nurses Need to Know

Abstract

The National Association of School Nurses supports immunization to reduce the incidence of vaccine-preventable diseases. School nurses have the obligation to discern and understand vaccine strategies to aid in the advocacy and education of their school administrators, faculty, staff, students, and caregivers. Coronavirus disease 2019 (COVID-19) has spread to all continents, and the total number of those infected or immune through effective vaccination is well below the estimated need for herd immunity. To achieve herd immunity against the global outbreak of COVID-19, the rapid development of safe and effective vaccines is essential. Using multiple strategies and vaccine platforms to speed up the vaccine development process will inherently save more lives. Equipped with this knowledge of vaccine strategy, the school nurse can more aptly advocate for the use of the COVID-19 vaccines to move toward herd immunity in their communities.

Keywords

COVID-19 vaccine strategy vaccine platforms advocacy education wellness

Get full access to this article

View all access options for this article.

References

Böttcher

Nagler

(2021). Decisive conditions for strategic vaccination against SARS-CoV-2. medRxiv. https://doi.org/10.1101/2021.03.05.21252962

Callaway

(2020). The race for coronavirus vaccines: A graphical guide. Nature, 580(7805), 576-577. https://doi.org/10.1038/d41586-020-01221-y

Centers for Disease Control and Prevention. (2021a). CDC recommends use of Johnson & Johnson’s Janssen COVID-19 vaccine resume. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/JJUpdate.html

Centers for Disease Control and Prevention. (2021b). Ensuring COVID-19 vaccines work. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/effectiveness.html

Centers for Disease Control and Prevention. (2021c). How do I find a COVID-19 vaccine? https://www.cdc.gov/coronavirus/2019-ncov/vaccines/How-Do-I-Get-a-COVID-19-Vaccine.html

Centers for Disease Control and Prevention. (2021d). How to talk about COVID-19 vaccines with friends and family. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/talk-about-vaccines.html

Centers for Disease Control and Prevention. (2021e). Myths and facts about COVID-19 vaccines. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/facts.html

Centers for Disease Control and Prevention. (2021f). Possible side effects after getting a COVID-19 vaccine. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/expect/after.html

Centers for Disease Control and Prevention. (2021g). Variants of the virus that causes COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html

10.

Centers for Disease Control and Prevention. (2021h). When you’ve been fully vaccinated. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html

11.

Chakraborty

Sharma

A. R.

Bhattacharya

Sharma

Saha

R. P.

Lee

S. S.

(2021). Ongoing clinical trials of vaccines to fight against COVID-19 pandemic. Immune Network, 21(1), e5. https://doi.org/10.4110/in.2021.21.e5

12.

Dong

Gardner

(2020). An interactive web-based dashboard to track COVID-19 in real time. Lancet Infectious Diseases, 20(5), 533-534. https://doi.org/10.1016/s1473-3099(20)30120-1

13.

Fomsgaard

Liu

M. A.

(2021). The key role of nucleic acid vaccines for one health. Viruses, 13(2), Article 258. https://doi.org/10.3390/v13020258

14.

Gordon

Reynolds

Barnby

(2021). An informative discussion for school nurses on COVID-19 mRNA vaccine. NASN School Nurse, 36(3), 132-136. https://doi.org/10.1177/1942602X21999606

15.

Honigsbaum

Krishnan

(2020). Taking pandemic sequelae seriously: From the Russian influenza to COVID-19 long-haulers. Lancet, 396(10260), 1389-1391. https://doi.org/10.1016/s0140-6736(20)32134-6

16.

Karpiński

T. M.

Ożarowski

Seremak-Mrozikiewicz

Wolski

Wlodkowic

(2021). The 2020 race towards SARS-CoV-2 specific vaccines. Theranostics, 11(4), 1690-1702. https://doi.org/10.7150/thno.53691

17.

Lawton

(2021). Sights set on universal vaccine. New Scientist, 249(3323), 8-9. https://doi.org/10.1016/s0262-4079(21)00302-x

18.

Lee

Kim

C. U.

Seo

S. H.

Kim

D. J.

(2021). Current status of COVID-19 vaccine development: Focusing on antigen design and clinical trials on later stages. Immune Network, 21(1), e4. https://doi.org/10.4110/in.2021.21.e4

19.

Majid

Khan

M. S.

Rashid

Niyaz

Farooq

Bhat

S. A.

Wani

H. A.

Qureshi

(2021). COVID-19: Diagnostics, therapeutic advances, and vaccine development. Current Clinical Microbiology Reports. Advance online publication. https://doi.org/10.1007/s40588-021-00157-9

20.

Makarov

Riabova

Ekins

Pluzhnikov

Chepur

(2020). The past, present and future of RNA respiratory viruses: influenza and coronaviruses. Pathogens and Disease, 78(7). https://doi.org/10.1093/femspd/ftaa046

21.

National Association of School Nurses. (2016). Framework for 21st Century School Nursing Practice. NASN School Nurse, 31(1), 45-53. https://doi.org/10.1177/1942602X15618644

22.

National Association of School Nurses. (2020). Immunizations (Position statement).

23.

Oliver

S. E.

Gargano

J. W.

Scobie

Wallace

Hadler

S. C.

Leung

Blain

A. E.

McClung

Campos-Outcalt

Morgan

R. L.

Mbaeyi

MacNeil

Romero

J. R.

Talbot

Lee

G. M.

Bell

B. P.

Dooling

(2021). The Advisory Committee on Immunization Practices’ interim recommendation for use of Janssen COVID-19 vaccine, United States, February 2021. MMWR Morbidity and Mortality Weekly Report, 70(9), 329-332. https://doi.org/10.15585/mmwr.mm7009e4

24.

Park

Cartmill

Johnson-Gordon

(2021). Preparing for a school-located COVID-19 vaccination clinic. NASN School Nurse, 36(3), 156-163. https://doi.org/10.1177/1942602X21991643

25.

Pascolo

(2021). Synthetic messenger RNA-based vaccines: from scorn to hype. Viruses, 13(2), Article 270. https://doi.org/10.3390/v13020270

26.

Pawlowski

Puranik

Bandi

Venkatakrishnan

A. J.

Agarwal

Kennedy

O’Horo

J. C.

Gores

G. J.

Williams

A. W.

Halamka

Badley

A. D.

Soundararajan

(2021). Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations. Scientific Reports, 11(1), Article 4741. https://doi.org/10.1038/s41598-021-83641-y

27.

Roncati

Corsi

(2021). Nucleoside-modified messenger RNA COVID-19 vaccine platform. Journal of Medical Virology. Advance online publication. https://doi.org/10.1002/jmv.26924

28.

Sarwar

Ahmad

Kakar

(2020). Potential approaches to combat COVID-19: A mini-review. Molecular Biology Reports, 47(12), 9939-9949. https://doi.org/10.1007/s11033-020-05988-1

29.

Sharmin

Islam

A. B.

(2014). A highly conserved WDYPKCDRA epitope in the RNA directed RNA polymerase of human coronaviruses can be used as epitope-based universal vaccine design. BMC Bioinformatics, 15, Article 161. https://doi.org/10.1186/1471-2105-15-161

30.

Stefano

G. B.

(2021). Historical insight into infections and disorders associated with neurological and psychiatric sequelae similar to long COVID. Medical Science Monitor, 27, e931447. https://doi.org/10.12659/msm.931447

31.

Strizova

Smetanova

Bartunkova

Milota

(2021). Principles and challenges in anti-COVID-19 vaccine development. International Archives of Allergy and Immunology, 182(4), 339-349. https://doi.org/10.1159/000514225

32.

Thanh Le

Andreadakis

Kumar

Gómez Román

Tollefsen

Saville

Mayhew

(2020). The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery, 19(5), 305-306. https://doi.org/10.1038/d41573-020-00073-5

33.

Triggle

C. R.

Bansal

Ding

Islam

M. M.

Farag

Hadi

H. A.

Sultan

A. A.

(2021). A Comprehensive review of viral characteristics, transmission, pathophysiology, immune response, and management of SARS-CoV-2 and COVID-19 as a basis for controlling the pandemic. Frontiers in Immunology, 12, 631139. https://doi.org/10.3389/fimmu.2021.631139

34.

World Health Organization. (2020). Guidelines for assuring the quality, safety, and efficacy of plasmid DNA vaccines-Post ECBS version/1 September 2020. https://www.who.int/publications/m/item/DNA-post-ECBS-1-sept-2020

35.

Yang

M. J.

Rooks

B. J.

T. T.

Santiago

I. O.

3rd Diamond

Dorsey

N. L.

Mainous

A. G.

3rd . (2021). Influenza vaccination and hospitalizations among COVID-19 infected adults. Journal of the American Board of Family Medicine, 34(Suppl.), S179-S182. https://doi.org/10.3122/jabfm.2021.S1.200528

36.

Yokota

Miyamae

Kuroiwa

Nishioka

(2021). Novel coronavirus disease 2019 (COVID-19) and cytokine storms for more effective treatments from an inflammatory pathophysiology. Journal of Clinical Medicine, 10(4). https://doi.org/10.3390/jcm10040801

37.

Yuan

N. C.

Zhu

Lee

C. D.

R. T. Y.

Mok

C. K. P.

Wilson

I. A.

(2020). A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science, 368(6491), 630-633. https://doi.org/10.1126/science.abb7269